These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 27023060

  • 21. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, Viollet R, Thomas M, Roy S, Benannoune N, Tomasic G, Soria JC, Champiat S, Texier M, Lanoy E, Robert C.
    JAMA Dermatol; 2016 Jan; 152(1):45-51. PubMed ID: 26501224
    [Abstract] [Full Text] [Related]

  • 22. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
    Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L.
    J Immunother; 2016 Jan; 39(9):379-382. PubMed ID: 27662340
    [Abstract] [Full Text] [Related]

  • 23. The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
    Puri A, Homsi J.
    Melanoma Res; 2017 Oct; 27(5):519-523. PubMed ID: 28817445
    [Abstract] [Full Text] [Related]

  • 24. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
    Hanna KS.
    Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
    [Abstract] [Full Text] [Related]

  • 25. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P, Gowrishankar K.
    Future Oncol; 2015 Nov; 11(1):133-40. PubMed ID: 25572788
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.
    Salomon G, Maza A, Boulinguez S, Paul C, Lamant L, Tournier E, Mazereeuw-Hautier J, Meyer N.
    Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis.
    Nader ME, Myers JN, Gidley PW.
    J Immunother Cancer; 2017 May; 5():24. PubMed ID: 28331614
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [Abstract] [Full Text] [Related]

  • 31. Pembrolizumab: first global approval.
    Poole RM.
    Drugs; 2014 Oct; 74(16):1973-1981. PubMed ID: 25331768
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Ipilimumab treatment of metastatic melanoma].
    Ghasemi H, Schmidt H, Stolle LB.
    Ugeskr Laeger; 2015 Jan 26; 177(2A):108-9. PubMed ID: 25612993
    [Abstract] [Full Text] [Related]

  • 35. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec 26; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

  • 36. Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
    Kothapalli A, Khattak MA.
    Melanoma Res; 2018 Apr 26; 28(2):155-158. PubMed ID: 29406396
    [Abstract] [Full Text] [Related]

  • 37. The safety of anti PD-1 therapeutics for the treatment of melanoma.
    Ramelyte E, Schindler SA, Dummer R.
    Expert Opin Drug Saf; 2017 Jan 26; 16(1):41-53. PubMed ID: 27737598
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
    Sepúlveda M, Martinez-Hernandez E, Gaba L, Victoria I, Sola-Valls N, Falgàs N, Casanova-Molla J, Graus F.
    Muscle Nerve; 2017 Dec 26; 56(6):E162-E167. PubMed ID: 28439919
    [Abstract] [Full Text] [Related]

  • 40. Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.
    van der Kooij MK, Joosse A, Speetjens FM, Hospers GA, Bisschop C, de Groot JW, Koornstra R, Blank CU, Kapiteijn E.
    Acta Oncol; 2017 Jan 26; 56(1):101-103. PubMed ID: 27911126
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.